Stay updated with the latest CAR-T therapy reports for lymphoma treatment in China. This section highlights key clinical results, real-world effectiveness, safety data, expert analyses, and major developments in DLBCL, FL, MCL, and other lymphoma subtypes. Designed for international patients and medical professionals, it provides clear, reliable insights into how China is advancing CAR-T therapy and improving outcomes for lymphoma care.
A patient with high-risk POD24 follicular lymphoma achieved durable complete remission after treatment with Carteuva CD19 CAR-T therapy. This case highlights the growing role of CAR-T therapy in patients with early relapse and limited treatment options.
At ASH 2025, researchers from Shenzhen University General Hospital reported updated Phase I/II data showing CD19/CD20 dual-target CAR-T therapy achieved a 77% ORR and durable responses with controllable safety in relapsed/refractory B-cell lymphoma.
A rare DLBCL patient with cold agglutinin syndrome achieved long-term complete remission after CD19 CAR-T therapy, showing CAR-T’s potential in complex lymphoma with autoimmune disease.
Alan from the Phillippines sharing his experience of getting CAR-T cell therapy at our affiliated medical center.
China’s domestically developed CAR-T therapy, Carteyva, is giving new hope to patients with relapsed/refractory lymphoma. From a personalized treatment process to promising survival data, this breakthrough cell therapy is reshaping the future of cancer care in China.
Relma-cel CAR-T therapy achieved complete remission in a high-risk, elderly R/R DLBCL patient, offering new hope where standard treatments failed.
In this video, we share the courageous journey of a patient diagnosed with mantle cell lymphoma (MCL), a rare and aggressive type of non-Hodgkin lymphoma. After undergoing multiple rounds of
A 57 yo high risk MCL achieved CR for two years after treatment with Carveyta, a innovative CAR T-cell therapy recently received
A patient sharing her experience five years after CAR T-cell therapy for lymphoam treatment.
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.